Shanghai Runda Medical Technology Co., Ltd. (603108.SS)
CNY 18.05
(0.06%)
CNY 18.05
(0.06%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 5.96 Billion CNY | 1.86% |
| 2022 | 5.85 Billion CNY | 25.55% |
| 2021 | 4.66 Billion CNY | 27.54% |
| 2020 | 3.65 Billion CNY | 64.03% |
| 2019 | 2.22 Billion CNY | 8.79% |
| 2018 | 2.04 Billion CNY | -15.09% |
| 2017 | 2.41 Billion CNY | 548.03% |
| 2016 | 372.48 Million CNY | 3.89% |
| 2015 | 358.55 Million CNY | 95.09% |
| 2014 | 183.79 Million CNY | 160.98% |
| 2013 | 70.42 Million CNY | 1185.67% |
| 2012 | -6.48 Million CNY | 51.9% |
| 2011 | -13.48 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 5.55 Billion CNY | -17.38% |
| 2024 Q1 | 5.83 Billion CNY | -2.12% |
| 2024 Q2 | 5.83 Billion CNY | -0.09% |
| 2023 Q3 | 6.09 Billion CNY | -1.49% |
| 2023 Q2 | 6.19 Billion CNY | 1.08% |
| 2023 Q1 | 6.12 Billion CNY | 4.56% |
| 2023 FY | 5.96 Billion CNY | 1.86% |
| 2023 Q4 | 5.96 Billion CNY | -2.17% |
| 2022 Q4 | 5.85 Billion CNY | -1.87% |
| 2022 Q2 | 5.43 Billion CNY | 5.4% |
| 2022 FY | 5.85 Billion CNY | 25.55% |
| 2022 Q1 | 5.15 Billion CNY | 10.6% |
| 2022 Q3 | 5.96 Billion CNY | 9.76% |
| 2021 FY | 4.66 Billion CNY | 27.54% |
| 2021 Q1 | 4.4 Billion CNY | 20.47% |
| 2021 Q2 | 4.43 Billion CNY | 0.55% |
| 2021 Q3 | 5.05 Billion CNY | 14.16% |
| 2021 Q4 | 4.66 Billion CNY | -7.77% |
| 2020 Q4 | 3.65 Billion CNY | -1.59% |
| 2020 Q1 | 2.85 Billion CNY | 28.08% |
| 2020 Q2 | 3.22 Billion CNY | 13.04% |
| 2020 FY | 3.65 Billion CNY | 64.03% |
| 2020 Q3 | 3.71 Billion CNY | 15.12% |
| 2019 Q4 | 2.22 Billion CNY | 5.85% |
| 2019 Q2 | 2.06 Billion CNY | -0.55% |
| 2019 Q3 | 2.1 Billion CNY | 2.15% |
| 2019 FY | 2.22 Billion CNY | 8.79% |
| 2019 Q1 | 2.07 Billion CNY | 1.18% |
| 2018 Q2 | 2.26 Billion CNY | -9.91% |
| 2018 FY | 2.04 Billion CNY | -15.09% |
| 2018 Q4 | 2.04 Billion CNY | 0.63% |
| 2018 Q3 | 2.03 Billion CNY | -9.93% |
| 2018 Q1 | 2.51 Billion CNY | 3.98% |
| 2017 Q2 | 1.25 Billion CNY | 41.83% |
| 2017 FY | 2.41 Billion CNY | 548.03% |
| 2017 Q1 | 886.28 Million CNY | 137.94% |
| 2017 Q4 | 2.41 Billion CNY | 21.25% |
| 2017 Q3 | 1.99 Billion CNY | 58.37% |
| 2016 Q1 | 403.72 Million CNY | 12.6% |
| 2016 Q4 | 372.48 Million CNY | -56.28% |
| 2016 Q3 | 851.91 Million CNY | 51.24% |
| 2016 Q2 | 563.29 Million CNY | 39.52% |
| 2016 FY | 372.48 Million CNY | 3.89% |
| 2015 FY | 358.55 Million CNY | 95.09% |
| 2015 Q1 | 290.91 Million CNY | 58.29% |
| 2015 Q2 | -8.98 Million CNY | -103.09% |
| 2015 Q3 | 245.92 Million CNY | 2837.45% |
| 2015 Q4 | 358.55 Million CNY | 45.79% |
| 2014 FY | 183.79 Million CNY | 160.98% |
| 2014 Q1 | 182.57 Million CNY | 0.0% |
| 2014 Q2 | 136.06 Million CNY | -25.48% |
| 2014 Q4 | 183.79 Million CNY | 0.0% |
| 2013 FY | 70.42 Million CNY | 1185.67% |
| 2012 FY | -6.48 Million CNY | 51.9% |
| 2011 FY | -13.48 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Joinn Laboratories(China)Co.,Ltd. | -2.77 Billion CNY | 314.827% |
| WuXi AppTec Co., Ltd. | -4.24 Billion CNY | 240.484% |
| Autobio Diagnostics Co., Ltd. | -448.29 Million CNY | 1430.831% |
| Thalys Medical Technology Group Inc. | 772.55 Million CNY | -672.246% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | -1.87 Billion CNY | 417.564% |
| Chemclin Diagnostics Co., Ltd. | -214.05 Million CNY | 2887.143% |